Therefore, it is reasonable to postulate that although CYP2D6 activity is diminished in IMs, the metabolic capacity of the encoded enzyme is still capable of converting tamoxifen to its active form at adequate concentrations to competitively antagonize ERs in tumor breast cancer tissues. This evidence concerns the gene CYP2D6 and breast carcinoma.